About Us

Equillium is a clinical-stage biopharmaceutical company developing novel immune-modifying therapies for severe immuno-inflammatory diseases. Our lead asset, itolizumab, targets the CD6-ALCAM signaling pathway, which plays a central role in the activity and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. Itolizumab has potential to be a best-in-class disease-modifying therapeutic and is currently being evaluated in clinical trials in multiple indications, including a planned pivotal study in acute graft-versus-host-disease (aGVHD), an ongoing Phase 1b study in lupus/lupus nephritis and an ongoing Phase 1b study in uncontrolled asthma.

Executive Team

Board of Directors

Scientific and Clinical Advisors


Equillium acquired rights for developing and commercializing itolizumab in the U.S., Canada, Australia and New Zealand through an exclusive collaboration and license agreement with Biocon.